Accessibility Menu

Why This Fund Cashed Out of a $3.6 Million Biotech ETF Bet

After a strong biotech rebound, one fund quietly walked away from sector beta, and the timing says more than the trade itself.

By Jonathan Ponciano Dec 26, 2025 at 3:53PM EST

Key Points

  • Kentucky-based Aristides Capital sold 28,467 shares of IBB in the third quarter.
  • The shares were worth an estimated $3.60 million.
  • The move marked a full exit from the position, which was previously about 1.18% of the fund's AUM.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.